The Zion Medical-based pharmaceutical company, which recently broke the news of a successful first clinical trial of what they called HIV treatment, issued a further statement on Twitter, making it clear that more testing and testing will be needed. that official results should be published and evaluated by peers.
Since the company made the announcement on October 31, there has been a surge of enthusiasm in the social media in particular, with people shouting for more information about "possible treatment".
According to the World Health Organization, by the end of 2017, about 36.9 million people worldwide lived with HIV.
In a statement at the time, Zion Medical announced the results of the first clinical trial of HIV-drug Gammora, which, according to the company, eliminated up to 99% of the HIV virus within four weeks of treatment.
Nine HIV-infected patients participated in the "Part I and II" trial at the Dr. Ronald Bata Memorial in Entebbe, over a 10-week period.
But the company has moved to moderate expectations, by saying on Twitter: "We want to thank everyone for their interest in the promising results of our first clinical trial." Like you, we hope that #Gammora can offer one day to those who have been affected by #HIV a viable pathway to get rid of an infection. including additional trials, the publication of results and the steps required to make #Gammora commercially available.
"We are not yet there, but we are one step closer, promising – and committed to informing you of our progress."
The company also acknowledged that the official results should be peer-reviewed in a scientific journal, which it hopes will have done in early 2019.
Professor Adrian Puren, head of the Diagnostic Monitoring and Survival Diagnostic Unit at the National Institute of Communicable Diseases (NICD), told Health24 that there is a long process to be followed before being bold enough to call for drug therapy.
"You will need to go through several stages to prove this. Carrying out the research, collecting evidence and creating what is needed to find some potential is important.
"There are different phases that you should spend too. You may need to do an animal test, then a small human test – the procedure is complex and you may need to start very small and perform several tests to find that medicines are not toxic and there are no harmful side effects.
"You will also need to test the efficacy of the drug at various stages, going through the various phases of the tests. At some stage you will also need to run randomized exams to eliminate the bias from research and make sure that people are not "that are hurt.
"To go through this is not easy, it is very complex, it has to be detailed and expensive enough to see this medicine, I want to see the published bibliography and we can find everything behind the editors, knowing that everything has been reviewed.
"Once the entire survey has been reviewed and conducted by all regulatory authorities, by various board of ethics and adequately considered, then a company will be able to make such a statement, and when they do so, it usually happens in large conferences "Said Puren.
Deputy Director General of the Department of Health for HIV / AIDS, Tuberculosis and Mother, Child and Female Health, Dr Yogan Pillay, added: "To our knowledge, there are no published clinical trials about it.
"Unless published in scientific journals and the World Health Organization approves this medicine, we can not take it seriously."
On Tuesday, a prominent HIV scientist hit the "cure", which was widely spread in the social media, like the hit of the "spoon".
"The world of HIV has been experiencing pandas in various forms for decades – unfortunately, it confuses most of them," said Professor Francois Venter of the Witwatersrand University for Reproductive Health and the HIV Institute.
He said that by saying that the drug is a possible treatment without side effects is "over-the-top biological claims that appear to the public before the official literature [is published] and must be examined with deep skepticism. "
"I looked at the press release and the company's unexpected website, and even if you believe their claims are many years away from testing," Venter said.
Zion Medical is a relatively new company founded in 2014. According to the company's website, it develops products that treat AIDS and cancer based on HIV-derived peptides and target lentivirus particles.
He lists his associates, such as the Jerusalem Jewish University, Mount Sinai Hospital in New York (USA) and Tel-Aviv Sourasky Medical Center, among others.
All Health24 efforts to contact Zion Medical for further comments have so far failed – all forms of emails have not been delivered due to an invalid email address and all telephone calls have not been answered.